ASCO 2022 Breast/Gyn

CME

Key Studies in Breast and Gynecologic Cancers: Independent Conference Coverage of the 2022 ASCO Annual Meeting

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: August 17, 2022

Expiration: August 16, 2023

Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD
Angeles Alvarez Secord
Angeles Alvarez Secord, MD, MHSc

Activity

Progress
1
Course Completed
Introduction

In this activity, Joyce O’Shaughnessy, MD, and Angeles Alvarez Secord, MD, MHSc, review key breast and gynecologic cancer studies, respectively, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on new data.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional (HCP), how many patients with breast or gynecologic cancers do you provide care for in a typical month?
Based on the results of the DESTINY-Breast04 trial, for which of the following patient populations with breast cancer would you consider treatment with trastuzumab deruxtecan after failure of standard treatment options?
In a subset analysis from a randomized phase II trial recently reported by Howell and colleagues, patients with pretreated metastatic breast cancer and which of the following alterations showed the greatest benefit with the combination of capivasertib plus fulvestrant compared with fulvestrant plus placebo?
Which of the following findings was reported from the TROPiCS-02 trial for sacituzumab govitecan when compared with physician’s choice of chemotherapy?
You recently attended a presentation for the innovaTV 205 trial of tisotumab vedotin in combination with pembrolizumab or carboplatin in patients with recurrent or metastatic cervical cancer. After evaluating these data, which of the following was reported for tisotumab vedotin in combination?
At the 2022 ASCO Annual Meeting, Tewari and colleagues reported the subgroup analyses from the phase III KEYNOTE-826 trial of pembrolizumab combined with chemotherapy with or without bevacizumab. Which of the following findings reported from this analysis would affect how you plan to use the regimen of pembrolizumab combined with chemotherapy with or without bevacizumab?